Observational Study on Hereditary Cancer Genomic Testing to Improve Prevention and Early Detection in Adults 65 and Older

What this Trial Is About

Researchers are observing individuals aged 65 years or older who have undergone hereditary cancer genomic testing to understand how this testing can help assess genetic cancer risk and guide doctors in preventive care. The study focuses on hereditary cancer diagnostics to potentially enable early detection and treatment. It collects data related to patients medical history, demographics, physician recommendations, and genetic test results for certain genes linked to hereditary cancer risks. The study does not involve new treatments but collects data from patients who have already had hereditary cancer genomic tests ordered by their physicians for medical reasons. The genes tested may vary over time as new knowledge emerges. Data collection occurs retrospectively over a period of up to 150 days, primarily through one survey form, capturing information related to genetic tests and physician treatment recommendations. Participants provide consent for their data to be included, and the study records information such as medical history, demographic details, and physician specialty. Researchers analyze these data to evaluate the clinical utility of genetic testing for cancer prevention and early detection. An interim analysis will help determine if the number of participants or data collection duration should be adjusted. The overall observation period spans approximately 120 days.

Strategic Targeting for Optimal Prevention of Cancer